![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 29, 20578-20586, July 16, 1999
From Microbial metabolites isolated in screening
programs for their ability to activate transcription of the
tipA promoter (ptipA) in Streptomyces
lividans define a class of cyclic thiopeptide antibiotics having
dehydroalanine side chains ("tails"). Here we show that such
compounds of heterogeneous primary structure (representatives tested:
thiostrepton, nosiheptide, berninamycin, promothiocin) are all
recognized by TipAS and TipAL, two in-frame translation products of the
tipA gene. The N-terminal helix-turn-helix DNA binding
motif of TipAL is homologous to the MerR family of transcriptional
activators, while the C terminus forms a novel ligand-binding domain.
ptipA inducers formed irreversible complexes in
vitro and in vivo (presumably covalent) with TipAS by
reacting with the second of the two C-terminal cysteine residues.
Promothiocin and thiostrepton derivatives in which the dehydroalanine
side chains were removed lost the ability to modify TipAS. They were able to induce expression of ptipA as well as the
tipA gene, although with reduced activity. Thus, TipA
required the thiopeptide ring structure for recognition, while the tail
served either as a dispensable part of the recognition domain and/or
locked thiopeptides onto TipA proteins, thus leading to an irreversible
transcriptional activation. Construction and analysis of a disruption
mutant showed that tipA was autogenously regulated and
conferred thiopeptide resistance. Thiostrepton induced the synthesis of
other proteins, some of which did not require tipA.
Directed searches for microbial secondary metabolites that inhibit
bacterial growth led to the discovery of antibiotics and thus gave rise
to the traditional interpretation that their only biological relevance
is to inhibit growth of competing organisms. Nevertheless, antibiotics
often have alternative molecular targets and, like other secondary
metabolites, elicit numerous "unexpected" effects on microbial
differentiation (1-4) and mammalian cell function (1). Here we
describe how a single transcriptional activator can interact with
diverse thiopeptide antibiotics to elicit autogenous expression of its
own promoter as well as a modulon in Streptomyces lividans
(SL).1
Thiopeptides are a family of antibiotics composed of a ring structure
containing highly modified amino acids and a linear peptide containing
dehydroalanines extending from the ring at a pyridyl group ("tail")
(Fig. 1). They were first discovered as antibiotics synthesized by
diverse bacteria including Streptomyces, Bacillus, and Micrococcus. These compounds later
proved to be effective growth promotants for domestic animals (2-4),
an effect whose biological basis is not clear. Thiostrepton, whose
antibiotic activity is best understood, acts by binding tightly to the
procaryotic ribosome and thus inhibiting translation (5-8). In a
thiostrepton-producing organism, Streptomyces azureus,
methylation of a specific nucleotide in the 23 S rRNA can provide
resistance. Such methylated ribosomes do not bind and are therefore not
sensitive to thiostrepton (9). The gene encoding this methylase
(tsr) was originally cloned as an antibiotic resistance
determinant (10) and has been incorporated into most
Streptomyces cloning vectors (11-13).
Routine use of thiostrepton to select for tsr-containing
vectors in S. lividans revealed several unexpected
biological activities. Thiostrepton made S. lividans more
resistant to a variety of structurally heterogeneous antibiotics (Ref.
14, and references therein) and caused accumulation of
thiostrepton-induced proteins
(Tip). Two of these proteins, TipAL and TipAS, proved to be alternate in-frame translation products of the same gene (15) (tipA,
Fig. 2). At its N terminus, TipAL contained a conserved
helix-turn-helix DNA binding motif that defined it as a member of the
MerR family of transcriptional activators. The non-homologous
C-terminal domains of these genes interact with different low molecular
weight compounds: MerR with mercuric ion (16, 17), BmrR and BltR with
rhodamine 6G and tetraphenylphosphonium chloride (18), and SoxR with an unknown compound (19) reflecting superoxide anion toxicity (20). A
structural basis for multidrug recognition has recently been revealed
by the crystal structure of the binding domain of BmrR complexed with
tetraphenylphosphonium chloride (21). After binding the respective
regulators, these proteins activate transcription of corresponding
regulons that confer resistance to mercury (MerR), superoxide stress
(SoxR), or diverse antibiotics and antiseptics (SoxR, BmrR, and BltR).
The corresponding C-terminal region of TipAL, lacking the
helix-turn-helix motif, is translated independently in vast molar
excess as TipAS. Both TipAS and TipAL can covalently bind thiostrepton
(22). A reaction between a dehydroalanine residue in thiostrepton and
one of two C-terminal cysteines (Fig. 2) creates an antibiotic-TipAL
complex (23) that activates transcription of a monocistronic mRNA
from the tipA promoter (ptipA) (22).
Broad Spectrum Thiopeptide Recognition Specificity of the
Streptomyces lividans TipAL Protein and Its Role in
Regulating Gene Expression*
§,
,
,
,
¶¶
Biozentrum, Department of Microbiology,
University of Basel, Klingelbergstrasse 70, CH-4056 Basel, Switzerland,
¶ Shionogi Research Laboratories, Shionogi & Co., Ltd., 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002, Japan,
Dipartimento di Biologia Cellulare e dello Sviluppo, Sezione di
Genetica, Università di Palermo, Parco d'Orleans, 90128 Palermo,
Italy, ** Institute of Microbiology, Czech Academy of Sciences,
Videnska 1083, CZ-14220 Praha-4, Czech Republic,

Korea Research Institute of Bioscience and
Biotechnology, P. O. Box 115, Yusong, Taejon 305-600, Korea, and
§§ Institute of Molecular and Cellular
Biosciences, University of Tokyo, Bunyko-ku, Tokyo 113, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (21K):
[in a new window]
Fig. 1.
Chemical structures of thiopeptide inducers
of ptipA. Inducers of ptipA expression include:
A, thiostrepton (1664 Da); B, nosiheptide (1222 Da); C, berninamycin (A, 1147 Da; B, 1363 Da); and
D, promothiocin (A, 800 Da; MO, 762 Da; MN, 747 Da). These
antibiotics are characterized by a pyridine or reduced pyridyl moiety
with a macrocycle-containing thiazoles or oxazoles. The tail of these
structures corresponds to a linear peptide extension from the pyridyl
ring on the macrocycle.

View larger version (18K):
[in a new window]
Fig. 2.
Primary structure of TipAS and TipAL
proteins. The N-terminal domain of TipAL has sequence similarity
to other transcriptional regulators of the merR family
(soxR, bmrR, bltR, and ywnD
identified in the Bacillus subtilis genome sequencing
project; Ref. 59) with putative helix-turn-helix motifs
(H-T-H). TipAS and TipAL share a C-terminal domain
containing the only two cysteines (Cys-98 and Cys-105). The fact that
V8 peptidase cleaved (arrows) at a glutamate residue between
the two cysteines allowed mapping of the modified residue to Cys-105
(Fig. 6).
The ptipA has proven to be a valuable tool that has led to the discovery of new antibiotics. When actinomycete metabolite libraries, a traditional source of molecular diversity, were empirically screened for ptipA-inducing activities, 15 compounds were identified (24-27). While they had quite different chemical structures, all were thiopeptides having antibiotic activity.
Since the TipA proteins are found in Streptomyces strains
not known to have the thiopeptide biosynthetic genes, it is unclear what metabolic signals are the natural inducers of tipA.
Here we investigate the TipAL regulon and thiopeptide structural motifs that are important for TipA interactions.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Chemicals and Reagents-- Compounds used in these studies included (sources indicated in parentheses): thiostrepton A (hereafter referred to as thiostrepton; Squibb); nosiheptide and pristinamycin II (Rhône Poulenc); thiostrepton B (Eric Cundliffe, University of Leicester); viomycin (Pfizer); berninamycin A and B (Upjohn Chemicals); GE 2270A (Biosearch Italia); nisin A (Harry Rollema and Oscar Kuipers, Netherlands Institute for Dairy Research); diketopiperazines (Matthew Holden and Gordon Roberts, University of Nottingham); and farnesol, shikimic acid, and cerulenin (Fluka); other thiopeptides have been purified as described previously (32-35). L-[35S]Methionine protein labeling mix (7.9 mCi/ml L-[35S]methionine and 2.4 mCi/ml L-[35S]cysteine) was from NEN Life Science Products. Me2SO was purified by passing through dry alumina and dry silica columns.
Promothiocins MO and MN were isolated from the methanolysate of promothiocin B. Dried amberlite 15 (1 g) was added to a solution of promothiocin B (90 mg) in 3 ml of methanol. This mixture was refluxed for 24 h under N2 and then dried under reduced pressure. The residue, dissolved in 2 ml of chloroform/methanol (5:1), was applied to preparative silica TLC plates and developed with chloroform/methanol (15:1). The two spots with RF values of 0.59 and 0.51 corresponded to promothiocin MO and MN, respectively. Both spots were scraped off the plates and then purified further by preparative HPLC (YMC-packed C18 column, 20 × 250 mm, with a flow rate of 18 ml/min). The HPLC column was run with a gradient of acetonitrile and water to yield the purified promothiocins (32 mg of MO eluted at 38% acetonitrile; 21 mg of MN eluted at 33% acetonitrile).
Promothiocin MO was a white crystalline powder. The HRFAB-MS spectrum had a MH+ species with m/z of 762.2175, which corresponded to a molecular formula C34H35N9O8S2 (theoretical 762.2128 Da). 1H NMR of promothiocin MO in CDCl3/CD3OD (9:1) had resonance peaks at 8.55 ppm (1H, d, J = 7.9 Hz), 8.20 ppm (1H, d, J = 8.2 Hz), 8.07 ppm (1H, s), 8.01 ppm (1H, s), 5.38 ppm (1H, q, J = 7.0 Hz), 5.30 ppm (1H, q, J = 7.0 Hz), 4.70 ppm (1H, d, J = 16.2 Hz), 4.35 ppm (1H, d, J = 6.4 Hz), 4.12 ppm (1H, d, J = 16.2 Hz), 4.00 ppm (3H, s), 2.53 ppm (3H, s), 2.51 ppm (3H, s), 2.22 ppm (1H, m), 1.62 ppm (3H, d, J = 7.0 Hz), 1.54 ppm (3H, d, J = 7.0 Hz), 1.54 ppm (3H, d, J = 7.0 Hz), and 1.01 ppm (6H, d, J = 6.7 Hz).
Promothiocin MN was a white crystalline powder. The HRFAB-MS spectrum had a MH+ species with m/z of 747.2086, which corresponded to a molecular formula C33H34N10O7S2 (theoretical 747.2132 Da). 1H NMR of promothiocin MN in CDCl3/CD3OD (9:1) had resonance peaks at 8.44 ppm (1H, d, J = 8.2 Hz), 8.21 ppm (1H, d, J = 8.2 Hz), 8.07 ppm (1H, s), 8.03 ppm (1H, s), 5.39 ppm (1H, q, J = 7.0 Hz), 5.34 ppm (1H, q, J = 7.0 Hz), 4.65 ppm (1H, d, J = 16.2 Hz), 4.37 ppm (1H, d, J = 6.1 Hz), 4.15 ppm (1H, d, J = 16.2 Hz), 2.52 ppm (3H, s), 2.39 ppm (3H, s), 2.24 ppm (1H, m), 1.62 ppm (3H, d, J = 6.7 Hz), 1.60 ppm (3H, d, J = 7.0 Hz), 1.01 ppm (3H, d, J = 6.7 Hz), and 1.00 ppm (3H, d, J = 7.0 Hz).
Bacterial Strains and Plasmids-- Escherichia coli TG1 was used as a host for pUC19 and its derivatives. E. coli S17-1 was used as a donor strain for conjugation to S. lividans. pPS24 was the source of the viomycin resistance gene (28). TipA studies were done using SL carrying pAK114 (SL/pAK114) (15).
Growth Conditions--
S. lividans spores produced on
MS plates (1% agar containing 2% mannitol and 2% soybean meal) were
filtered through cotton, and stored in 20% glycerol at
20 °C.
Liquid cultures of SL/pIJ486 were grown in YEME medium (29). E. coli strains were grown at 37 °C in Lysogeny broth using 100 mg/liter ampicillin or 50 mg/liter kanamycin for selection (30).
Nutrient agar was made from nutrient broth (plus 15 g/liter agar)
obtained from Eiken Chemical Co., Tokyo, Japan.
Thiostrepton Sensitivity Assay-- Thiostrepton sensitivity disc assays were performed using S. lividans strains spread on NE agar (31). Measured amounts of thiopeptide (in Me2SO) were applied on a paper disc, and the culture was incubated overnight at 30 °C. Alternatively, the minimal amount of antibiotic required to inhibit colony formation on NE agar was determined.
In Vivo tipA Promoter Induction Assays-- The tipA promoter was cloned into pIJ486 in which a kanamycin resistance gene served as the reporter of promoter activity (15). This plasmid was used either in a disc (15) or plate assay. In the plate assay, SL/pAK114 spores were spread on nutrient agar supplemented with 10 µg/ml kanamycin and a series of 2-fold diluted thiopeptide compounds. The plate was scored for growth after 36-h of incubation at 30 °C.
Preparation of Purified TipA Proteins--
E. coli
cultures containing tipAL or tipAS expression
vectors were grown to late exponential phase in a 25-liter fermentor at
30 °C. Expression of tipA genes was induced by the
addition of 1 mM isopropylthiogalactoside for 3 h at
37 °C. The cells were collected by centrifugation at 10,000 × g for 30 min and stored at
20 °C. The cell paste was
suspended in the lysis buffer containing 400 mg/liter lysozyme and 10 mg/liter deoxyribonuclease I and stirred gently overnight (this and all
subsequent steps were carried out at 4 °C). Cell debris was removed
by centrifugation at 22,000 × g for 30 min to yield a
crude extract that was fractionated by adding solid ammonium sulfate to
reach 45% w/v saturation and then centrifuged at 22,000 × g for 15 min. Additional ammonium sulfate powder was added
to this supernatant to reach 90% w/v saturation. The pellet was
resuspended in three volumes of buffer (all subsequent steps were
carried out in MA buffer: 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 50 mM NaCl, 5 mM
MgCl2, and 5 mM dithiothreitol) and then
dialyzed. After centrifugation, the dialysate was applied to a
DEAE-Sepharose column and eluted using a gradient of 0-0.2 M NaCl. TipA-containing fractions were collected, dialyzed,
applied to a Q-Sepharose column (Amersham Pharmacia Biotech), and
eluted using a gradient of 0-0.5 M NaCl. TipA-containing
fractions were collected, dialyzed, applied to a Source-Q column, and
eluted in a gradient of 0-0.5 M NaCl. The fractions were
collected and concentrated with an Amicon Ultrafiltration cell with a
YM10 membrane. The concentrated solution was loaded on a Superose 12 HR
10/30 column (Amersham Pharmacia Biotech) and eluted isocratically. The
fractions containing the TipA protein were concentrated with Centricon
10 filters (Amicon).
Protein-Antibiotic Reactions-- Before reaction with thiostrepton or other antibiotics, TipAS or TipAL (10 µg in 15 µl of 50 mM Tris, pH 8.0, 1 mM EDTA) was reduced by the addition of sodium cyanoborohydride (2 µl of a freshly made 1 mM aqueous stock). After 5 min at room temperature, excess sodium cyanoborohydride was inactivated by adding 1 µl of acetone. Thiopeptides (10 µl of a 50 mg/liter purified Me2SO solution) were then added and the reaction was incubated at room temperature for 1 h. Protein products were desalted using a C4 HPLC column eluting with a gradient of 100% water to 75% acetonitrile/25% water. The proteins were subjected to SDS-PAGE or digested with V8 protease in 50 mM NaPO4, pH 7.0, at 37 °C for 24 h and analyzed with ESI-MS.
Electrophoretic Analyses--
Mycelium was collected by
centrifugation at 10,000 × g for 30 min, and then
washed with lysis buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 50 mM NaCl, 5 mM
MgCl2, 50 mg/liter benzamidine, 10 mg/liter leupeptin, 20 mM phenylmethanesulfonyl fluoride, and 5 mM
dithiothreitol) at 4 °C. Cells were resuspended in lysis buffer,
glass beads (0.1 mm diameter) were added to form a 30% v/v solution,
and the tube was cooled on ice for 10 min. The mycelia in this slurry
were sheared twice in a Bio-spec Products Minibead beater run at 3000 rpm for 1 min. The crude extract was centrifuged using a tabletop
centrifuge at 14,000 rpm for 5 min. Samples of the crude extract were
boiled for 3 min in a SDS-PAGE lysis buffer containing 20% w/v
glycerol, 6% SDS, 10% 2-mercaptoethanol, and 0.05% bromphenol blue
in 0.25 M Tris, pH 6.8. SDS-PAGE was carried out according
to Laemmli (32) or Schägger and von Jagow (33). Gels were stained
with Coomassie Blue (0.1% in 10% acetic acid), destained in 40%
ethanol/10% acetic acid, and equilibrated in 10% ethanol/3%
glycerol. After drying, radioactive spots were recorded on Fuji AIF-RX
medical x-ray film. Two-dimensional gel analyses were carried out as
described by Puglia et al. (34).
| |
RESULTS |
|---|
|
|
|---|
Construction of a Strain (KT) Having a Disrupted tipAL
Gene--
The tipA gene was disrupted to determine whether
it was required for thiopeptide-induced changes in gene expression. The
hygromycin resistance gene (hyg) was first inserted into the
5' region of the monocistronic tipA gene cloned in E. coli plasmid pAK315 (construction described in Fig. 3). pAK315 was
then transferred from E. coli S17-1 to S. lividans by conjugation (28). Since this plasmid cannot replicate
in S. lividans, it could only be maintained by integration
into the chromosome. Hygromycin-resistant and viomycin-sensitive (hygR/vioS) mutants would result from a double crossover event disrupting the tipA gene.
|
Total DNAs from SL and such hygR/vioS tipAL disruption candidates were digested with SacI or KpnI and probed with the 1.2-kb pAK108 SacI fragment which included the site of hyg insertion (blots not shown). In the parental strain, this probe hybridized to the 1.2-kb SacI fragment or a 3.5-kb KpnI fragment. These fragments were not present in the tipA::hygR disruption strain (KT); instead, the probe hybridized to 1.1- and 1.5-kb SacI and 5.1-kb KpnI fragments corresponding in size to that predicted for the hyg-disrupted tipA locus.
Inactivation of the tipA Gene Resulted in Sensitivity to Thiostrepton-- KT was compared with SL to determine whether disruption of tipA altered resistance to thiostrepton. An antibiotic disc sensitivity test revealed that about 5 times less thiostrepton was needed to obtain the same zones of inhibition on a KT lawn. This was further confirmed by streaking SL and KT out on the same medium containing increasing amounts of thiostrepton. Whereas the minimal inhibitory concentration for SL colony formation was 1 µg/ml, KT colony formation was inhibited by less than 0.2 µg/ml.
Thiopeptide-induced ptipA Expression Was Dependent on tipA-- The transcriptional activity of ptipA was monitored by cloning it into a Streptomyces promoter probe vector (pIJ486) so that it controlled a kanamycin resistance reporter gene (pAK114) (15). Induction of ptipA could be visualized with a sensitive disc assay. Agar plates containing kanamycin were overlaid with spores of the indicator strain SL/114 or KT/114. When discs containing thiostrepton were applied to the surface of the plate, induction of ptipA was indicated by a zone of kanamycin-resistant growth whose diameter was dependent on both the amount of kanamycin in the plate and the amount of thiopeptide inducer in the disc (15). In the absence of inducers, no kanamycin-resistant growth was observed on plates containing greater than 5 mg/liter kanamycin. Whereas this very sensitive assay was able to detect less than 2 ng of thiostrepton using the SL/pAK114 indicator strain, 1 mg elicited no response in the tipA mutant KT/pAK114 (lacking the intact tipAL gene) or SL/pIJ486 (lacking ptipA). These results showed that the reporter system had a strict requirement for both the ptipA and a functional tipA gene.
TipAL Controlled a Subset of the Thiostrepton-induced
Proteins--
Exponentially growing (15 h) or stationary phase
cultures (40 h) of SL/pIJ486 and KT/pIJ486 were induced with
thiostrepton (2 mg/liter) and labeled for 1 h with
[35S]methionine. The changes in protein expression
patterns that occur as a function of tipA and thiostrepton
as visualized by SDS-PAGE were complex (Fig. 4). Although the
thiostrepton response was noticeably different in exponential as
compared with stationary phase cultures, this was not studied in
detail. The exponential culture was more critically defined by
automated analysis of two-dimensional PAGE patterns (gels not shown).
Several thiostrepton-induced SDS-PAGE protein bands were observed in
SL/pIJ486 (Fig. 4, compare exponential growth (lanes
1 and 2) or stationary phase (lanes
5 and 6)). Seventeen thiostrepton-induced
two-dimensional PAGE protein spots were observed. Several of these
bands, including TipAS, were not found in KT (compare exponential
growth (lanes 2 and 4) or stationary
phase (lanes 6 and 8)); these
corresponded to eight two-dimensional PAGE protein spots. Finally,
these analyses also revealed thiostrepton-repressed SDS-PAGE bands in
both SL and KT; these corresponded to four two-dimensional PAGE spots
in SL and two in KT.
|
TipA Proteins Reacted in Vitro with Thiopeptides Having Dehydroalanine-containing Tails but Different Ring Structures-- TipAL and TipAS proteins were produced using an E. coli expression system. An NdeI/HindIII fragment of pNB2-5A1 containing tipAS was cloned into pDS8 (pMF101); an NdeI/HindIII fragment of pNB2-AL containing tipAL was cloned into pDS8 (pMF102) (22, 35-37). E. coli strains containing these constructions were able to produce large amounts of TipA proteins in a soluble form. These proteins were purified (see "Experimental Procedures") for in vitro studies.
Purified TipAS was mixed with thiostrepton, promothiocin A,
promothiocin B, nosiheptide, or berninamycin (A and B) (Fig.
1) and then analyzed by SDS-PAGE
(promothiocin B and thiostrepton are presented in Fig. 5A).
All of these compounds formed very stable complexes which could not be
disrupted in 1% SDS/1% 2-mercaptoethanol (boiling), 8 M
urea, or 6 M guanidine hydrochloride. Their apparent molecular masses corresponded roughly to uncomplexed TipAS (~17 kDa)
or TipAS bound to one molecule of thiopeptide (~18-19 kDa). ESI-MS
experiments of TipAS or TipAL mixed with nosiheptide or promothiocin A
confirmed that the TipA/thiopeptide stoichiometry was
equimolar.2
|
Previous studies using thiostrepton had shown these complexes were generated by a covalent reaction between a dehydroalanine residue in thiostrepton and one of the two cysteine residues in the TipA proteins (23). Thiostrepton has one dehydroalanine residue in the ring and two in the tail (Fig. 1). In order to map the reactive dehydroalanine residues to the ring or tail, a tailless derivative of thiostrepton (thiostrepton B, Fig. 1) was tested. Thiostrepton (Fig. 5A, lane 2) but not thiostrepton B (Fig. 5A, lane 4) altered the mobility of TipAS (Fig. 5A, lane 7) on SDS-PAGE gels.
To confirm the generality of this observation, tailless promothiocin derivatives MN (tail replaced by an amide group) and MO (tail replaced by an O-methyl group) were prepared from promothiocin B (Fig. 1) and purified to greater than 99.9% homogeneity (see "Experimental Procedures"). Promothiocin B was chosen as representative thiopeptide since it was composed of a simple ring structure having no dehydro amino acids and a tail containing three dehydroalanines (Fig. 1). TipAS formed a higher molecular mass complex with promothiocin B (Fig. 5A, lane 3) in a reaction presumably analogous to that with thiostrepton. This effect was dependent on the tail structure. Promothiocin derivatives MN (Fig. 5A, lane 5) and MO (Fig. 5A, lane 6) were nonreactive with TipAS.
TipA Proteins Reacted in Vivo with Thiopeptide Antibiotics Having Dehydroalanine-containing Tails but Different Ring Structures-- SDS-PAGE analyses of pulse-radiolabeled cultures demonstrated that various thiopeptides induced Tip proteins (Fig. 5B). TipAS-thiopeptide complexes, indistinguishable in size from those produced in vitro (Fig. 5A), were observed after induction using compounds having various ring structures including nosiheptide, berninamycin A and B, and promothiocins A and B (data not shown).
In order to test the requirement for the tail in vivo, thiostrepton- and promothiocin-induced proteins were compared with proteins induced by their tailless derivatives (Fig. 5). Tailless derivatives thiostrepton B, promothiocin MO, and promothiocin MN induced the synthesis of TipAS protein but not TipAS-antibiotic complexes. The absence of a TipAS complex after induction with thiostrepton B indicated that the dehydroalanine and dehydrobutyrine residues in the cyclic peptide domain did not participate in covalent TipAS complex formation. TipA proteins were not seen after the addition of any of these antibiotics to KT (data not shown).
Mapping the Reactive Cysteine in TipAS-- When TipAS or TipAL were pretreated with N-ethylmaleimide, they did not form protein complexes with promothiocin (A and B), berninamycin (A and B), or nosiheptide that could be observed by SDS-PAGE (data not shown). This confirmed that at least one of the cysteines in the TipA proteins was necessary for covalent binding.
V8 protease digestion of TipAS-thiostrepton complexes defined which
cysteine residue bound to thiostrepton. Cleavage at the glutamic acid
between the only two cysteines in TipAS generated unique peptide
fragments from both partial and complete digests. HPLC fractions of the
protease digests of TipAS with TipAS-thiostrepton complex were analyzed
with ESI-MS. Only the double and triple charged peptide fragment
containing the second cysteine residue (Cys-105 in TipAS) had an
additional molecular mass which corresponded to that of thiostrepton
(Fig. 6A). The experimental mass to charge ratios (1197.4, 1228.4) corresponded well with the theoretical values (1197.9, 1228.7)
of a peptide fragment containing Cys-105 reacted with one molecule of
thiostrepton. The fragment containing Cys-98 had a mass corresponding
to the peptide with its second cysteine unaltered (Fig. 6B).
It had an experimental mass to charge ratio of (646.1, 966.8) which
matched well with the corresponding theoretical values (967.4, 645.2).
No peaks corresponding to thiostrepton-reacted Cys-105 peptide were
found.
|
TipAL Ligand Specificity-- Most cyclic thiopeptide antibiotics induce ptipA (15, 26, 27). Visual comparison of these structures (Fig. 1) suggested common motifs that could be important for induction efficiency: dehydroalanine or dehydrobutyrine residues, quinaldic acid, thiazole, and pyridyl moieties. To screen compounds that might define the activity of these groups, plate or disc assays were adopted. Both were based on a reporter gene construction in which ptipA controlled the expression of the kanamycin resistance gene (pAK114; see "Experimental Procedures").
The minimal amount of various thiopeptides needed to allow ptipA-dependent kanamycin resistant growth (MinC) was semiquantified and thereby compared using the plate assay (Table I). MinC was defined as the minimal amount of thiopeptide needed to allow growth of SL/pAK114 on plates containing 10 mg/liter kanamycin. Thirteen of the 16 thiopeptides tested were active; however, the activity of different compounds varied considerably.
|
The MinC of the thiopeptides related to the number of dehydroalanine residues in the tail. The most active, promothiocin B (MinC = 0.6 ng/ml), has three dehydroalanine residues. Compounds with two (MinC = 1.2-2.4 ng) or one (MinC = 20-40 ng) dehydroalanines had progressively less activity. Thiopeptides whose tails had carboxyl termini were even less active (MinC = 40-80 ng), even though they contained four dehydroalanine residues. Compounds without dehydroalanine tails had reduced activity. In the case of thiostrepton, its activity was minimally reduced (about 3-fold) in its tailless analog, thiostrepton B. Chemical elimination of the promothiocin tail severely reduced its activity (more than 1000-fold) regardless of its remaining C-terminal group (amide in MN or carboxyl in MO).
Compounds that contained reactive vinyl groups (23) analogous to dehydroalanine were screened for ptipA induction using the disc assay. Acrylamide, cerulenin, fusidic acid, farnesol, N-ethylmaleimide, novobiocin, pristinamycin II, shikimic acid, and viomycin did not induce kanamycin-resistant growth. Nisin A, an antibiotic having several dehydroalanines, also did not induce kanamycin resistance.
In addition, analogs of residues in the ring structure including
quinaldic acid (nalidixic acid, menadione), a pyridyl group (diketopiperazines, pyridine, pyralinamide, and aniline), or thiazole (thiazolidine carboxylic acid) did not induce ptipA.
| |
DISCUSSION |
|---|
|
|
|---|
The tipA gene was initially viewed as a simple, thiostrepton-induced activator of its own transcription (22). Here we show that tipA serves as a multipeptide sensor and antibiotic resistance gene. Furthermore, we demonstrate that thiostrepton, in addition to being a ribosome-specific antibiotic, has other biological effects involving induction of both tipA dependent and independent modulons.
The observation that all thiopeptides which induce ptipA irreversibly altered the size of the TipA proteins not only facilitated detection of drug/protein interaction but also may have functional implications. Covalent interaction of these antibiotics with TipAL apparently increased their potency as activators of the tipA promoter. However, SDS-PAGE studies showed that compounds unable to covalently bind to TipAS (thiostrepton B, promothiocin MO and MN) were nevertheless able to induce the promoter as well as synthesis of unmodified TipAS. This provided evidence that covalent TipA-antibiotic complex formation was not necessary for thiopeptide-induced expression in vivo. Previous in vitro studies using a thiostrepton-binding column showed that TipA proteins were able to specifically and reversible associate with this ligand (22) (in these experiments, dithiothreitol in the buffer would have covalently reacted with thiostrepton, and thus irreversibly blocked the dehydroalanine residues). Together, these results showed that covalent attachment via the dehydroalanine tail was not required for stable interaction in vitro or in vivo, and that the ring contained a TipA recognition structure.
Comparisons of the ring structures of active peptides (such as
berninamycin, geninthiocin, promothiocins, nosiheptide, promoinducin, thiotipins, thioactin, thiostrepton, thioxamycin; representatives are
shown in Fig. 1) with those which were not active (Fig. 7, amythiamicins, cyclothiazomycins, and GE 2270A), suggested a minimal motif for TipAL recognition involving thiazole and pyridyl groups. Active compounds had a pyridyl group with attached thiazoles or oxazoles at the 4- or 5-positions which in turn were extended by linear
peptides. While inactive compounds (amythiamicin, cyclothiazomycin and
GE 2270A) have thiazoles or oxazoles similarly bound to the pyridyl
ring, they are extended by a bis-thiazole group rather than linear
peptides. In addition, cyclothiazomycin is substituted at the 1-, 2-, and 5-positions of the pyridyl ring. These observations suggested a
requirement for the pyridyl ring substitutions and the proximal
thiazoles or oxazoles.
|
In a cyclic peptide, internal ring structures as well as dehydro amino acids can provide conformational constraint on the peptide backbone and restrict the orientation of the adjacent amino acid side chains (38). Thiostrepton, which contains two dehydro amino acids in its double ring, is not highly dependent on its dehydroalanine tail to provide activity in vivo (i.e. thiostrepton B is only slightly less active than thiostrepton itself). On the other hand, promothiocin does not have dehydro amino acids in its single ring structure and is more than 1000 times more active than its tailless derivatives (MO and MN). This suggests that weaker inductions by such compounds may reflect a lower affinity constant rather than differences in their effect on TipAL conformation. Covalent binding probably locks TipAL into an active form, thereby serving as an irreversible switch.
The mechanism of transcriptional activation employed by well characterized proteins similar to TipAL, MerR, and SoxR involves changes in the oxidation state of cysteine residues located near their C termini. MerR activation is dependent on a protein dimer-Hg complex involving three cysteines; SoxR activation results from oxidation of an iron sulfur complex (2Fe/2S) involving two cysteine residues/protein. TipAL contains two C-terminal cysteine residues involved in activation. Thiostrepton, and presumably other active thiopeptides, react covalently with one of these cysteine residues. These two cysteine residues might form a reversible disulfide bond or iron sulfur cluster that reacts to redox conditions, and thus serve as a sensor. Modification of this structure by dehydroalanine and introduction of a bulky ring structure might irreversibly lock the protein in the transcriptionally active form.
Thus, our studies show that thiopeptides employ two different functional groups to elicit their effect on the TipAL protein. These include specific protein recognition structures (a portion of the ring) and a chain of thiol-reactive groups that form the tail. The fact that two unusual functional groups are combined in these highly active thiopeptides and that they react primarily with a specific protein suggests a unified biological function, i.e. transcriptional activation of ptipA. It is appealing to think that active thiopeptides are not only antibiotics but may serve as, or perhaps mimic, a physiological or developmental signal (22).
The tipA serves as an autogenously controlled antibiotic resistance system. When the tipA gene was disrupted, the strain became more sensitive to thiostrepton, berninamycin A, and nosiheptide. In response to thiostrepton, TipAL activates synthesis of a single mRNA that includes TipAS (15), an antibiotic-inactivating protein that apparently is much more efficiently translated. TipAS sequestration of thiostrepton would eventually limit activation of the TipAL-dependent promoter and thereby provide a self-contained low-level antibiotic resistance system.
Higher concentrations of thiostrepton that could be resisted by strains containing the tsr gene elicited a tipAL-independent effect on gene expression as observed by SDS- or two-dimensional PAGE. Synthesis of many proteins changed after induction of the tipA defective strain indicating involvement of another stress response system. Dehydro amino acids of thiostrepton are highly reactive toward low molecular weight thiols that maintain the cytoplasmic redox potential. In Actinomycetes, these include ovothiol A, ergothionine, and U17 present in the cytoplasm at millimolar concentrations (39-42). It seems unlikely that thiostrepton levels routinely used in labeling experiments or for selection of tsr-containing vectors (~10 µM) could reduce the concentrations of these compounds stoichiometrically and thereby disrupt overall cellular thiol balance. Amplification might be achieved by reactions between dehydroalanine and thiol-dependent redox regulatory compounds or proteins (other members of the tipA/soxR family have been uncovered by the Streptomyces coelicolor genome sequencing project). Disruption of redox balance would compromise systems for protein folding (43) and scavenging oxygen free radicals (44). Effects on metabolic flux might be effected through modulation of certain redox dependent enzymes (45, 46) or reduction in NADPH or NADH (47) pools.
Decreases in the redox potential are known to elicit increased
resistance to unrelated antibiotics and redox cycling agents. Thiostrepton induces resistance to antibiotics having different cellular targets including daunorubicin (48, 49), sparsomycin (50-52),
tetranactin (53), and GE2270A (54, 55). Interestingly, daunorubicin,
best known to interact with DNA, and sparsomycin, a ribosome inhibitor,
disrupt the redox balance of the cell (56-58). Characteristics of the
TipA proteins reported here, as well as its homology to MerR, SoxR,
BmrR, and BltR, suggest that it may directly regulate resistance to
stress induced by heavy metals, antibiotics, or redox, a concept we are
now exploring.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Tom Holt, Pat Griffin, and Paul Jeno for the mass spectrometry analyses and X.-M. Li for carrying out Southern blots.
| |
FOOTNOTES |
|---|
* This work was supported by Grant (SPP 5002-046085 (to C. J. T.) from the Swiss Biotechnology Priority Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: Dept. of Chemistry, McNulty Hall, Seton Hall University, South Orange, NJ 07079.
¶¶ To whom correspondence should be addressed. Tel.: 41-61-267-2116; Fax: 41-61-267-2118; E-mail: thompson@ubaclu.unibas.ch.
2 T. Holt and P. Griffin, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SL, Streptomyces lividans; KT, Streptomyces lividans containing a disrupted tipAL gene; J, spin-spin coupling constant; s, singlet; d, doublet; q, quartet; m, multiplet; HPLC, high pressure liquid chromatography; PAGE, polyacrylamide gel electrophoresis; m/z, mass to charge ratio; ESI-MS, electrospray ionization mass spectrometry; HRFAB-MS, high resolution fast atom bombardment mass spectrometry; hygR, resistant to hygromycin; vioS, sensitive to viomycin; kb, kilobase pair(s); Tricine, N-tris(hydroxymethyl)methylglycine.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Demain, A. L. (1995) Why Do Microorganisms Produce Antimicrobials? , Vol. 53 , pp. 50-75, Cambridge University Press, Cambridge, United Kingdom |
| 2. | Keppas, L., and DeGrote, F. (1979) Rev. Agric. Brussels 32, 159 |
| 3. |
Mine, K.,
Miyairi, N.,
Takano, N.,
Mori, S.,
and Watanabe, N.
(1972)
Antimicrob. Chemother.
1,
496-503 |
| 4. | Muir, L. A., Riches, E. L., Duquette, P. F., and Smith, G. E. (1980) J. Anim. Sci. 50, 547-553 |
| 5. | Cundliffe, E. (1987) Nature 69, 863-869[CrossRef] |
| 6. | Xing, Y., and Draper, D. E. (1996) Biochemistry 35, 1581-1588[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Rosendahl, F., and Douthwaite, S. (1993) J. Mol. Biol. 234, 1013-1020[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Draper, D. E. (1995) Nucleic Acids Symp. Ser. 33, 5-7 |
| 9. | Cundliffe, E. (1980) in Antibiotics and Procaryotic Ribosomes: Action, Interaction, and Resistance in Ribosomes Structure, Function, Genetics (Chambliss, G. , Craven, G. R. , Davies, J. , Davis, K. , Kahan, K. , and Nomura, M., eds) , pp. 555-581, University Park Press, Baltimore, MD |
| 10. |
Thompson, C. J.,
Skinner, R. H.,
Thompson, J.,
Ward, J. M.,
Haywood, D. A.,
and Cundliffe, E.
(1982)
J. Bacteriol.
151,
678-685 |
| 11. | Smokvina, T., Mazodier, M., Boccard, F., Thompson, C. J., and Guerineau, M. (1990) Gene (Amst.) 94, 53-59[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Kuhstoss, S., and Rao, R. N. (1991) Gene (Amst.) 103, 97-99[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Bibb, M. J., Ward, J. M., and Cohen, S. W. (1985) Mol. Gen. Genet. 199, 26-36[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Holmes, D. J., Caso, J. L., Katoh, T., and Thompson, C. J. (1993) in Industrial Microorganisms: Basic and Applied Molecular Genetics (Balz, R. H. , Hegeman, G. D. , and Skatrud, P. L., eds) , pp. 69-73, ASM, Washington, D. C. |
| 15. |
Murakami, T.,
Holt, T. G.,
and Thompson, C. J.
(1989)
J. Bacteriol.
171,
1459-1466 |
| 16. |
Helmann, J. D.,
Ballard, B. T.,
and Walsh, C. T.
(1990)
Science
247,
946-948 |
| 17. | Ansari, A. Z., Chael, M. L., and O'Halloran, T. V. (1992) Nature 355, 87-89[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Ahmed, M.,
Borsch, C. M.,
Taylor, S. S.,
Vazquez-Laslop, N.,
and Neyfakh, A. A.
(1994)
J. Biol. Chem.
269,
28506-28513 |
| 19. |
Gort, A. S.,
and Imlay, J. A.
(1998)
J. Bacteriol.
180,
1402-1410 |
| 20. | Hidalgo, E., and Demple, B. (1994) EMBO J. 13, 138-146[Medline] [Order article via Infotrieve] |
| 21. | Zheleznova, E. E., Markham, P. N., Neyfakh, A. A., and Brennan, R. G. (1999) Cell 96, 353-362[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Holmes, D. J., Caso, J. L., and Thompson, C. J. (1993) EMBO J. 12, 3183-3191[Medline] [Order article via Infotrieve] |
| 23. | Chiu, M. L., Folcher, M., Griffin, P., Holt, T., and Thompson, C. J. (1996) Biochemistry 35, 2332-2341[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Yun, B. S., Hidaka, T., Furihata, K., and Seto, H. (1994) J. Antibiot. 47, 1541-1545[Medline] [Order article via Infotrieve] |
| 25. | Yun, B. S., and Seto, H. (1995) Biosci. Biotechnol. Biochem. 59, 876-880[Medline] [Order article via Infotrieve] |
| 26. | Yun, B. S., Hidaka, T., Furihata, K., and Seto, H. (1995) J. Antibiot. 47, 969-975 |
| 27. | Yun, B. S., Hidaka, T., Furihata, K., and Seto, H. (1994) J. Antibiot. 47, 510-514[Medline] [Order article via Infotrieve] |
| 28. |
Mazodier, P.,
Petter, R.,
and Thompson, C.
(1989)
J. Bacteriol.
171,
3583-3585 |
| 29. | Hopwood, D. A., Bibb, M. J., Chater, K. F., Kieser, T., Bruton, C. J., Kieser, H. M., Lydiate, D. J., Smith, C. P., Ward, J. M., and Schrempf, H. (1985) Genetic Manipulation of Streptomyces: A Laboratory Manual , The John Innes Foundation, Norwich, England |
| 30. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, New York |
| 31. | Murakami, T., Anzai, H., Imai, S., Satoh, A., Nagaoka, K., and Thompson, C. J. (1986) Mol. Gen. Genet. 205, 42-50[CrossRef] |
| 32. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Schägger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Puglia, A. M., Vohradsky, J., and Thompson, C. J. (1995) Mol. Microbiol. 17, 737-746[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Campbell, J. L.,
Richardson, C. C.,
and Studier, F. W.
(1978)
Proc. Natl. Acad. Sci. U. S. A.
75,
2276-2280 |
| 36. |
Villarejo, M. R.,
and Zabin, I.
(1974)
J. Bacteriol.
120,
466-474 |
| 37. | Bujard, H., Gentz, R., Lanzer, M., Stueber, D., Mueller, M., Ibrahimi, I., Haeuptle, M.-T., and Dobberstein, B. (1987) Methods Enzymol. 155, 416-433[Medline] [Order article via Infotrieve] |
| 38. | Broda, M. A., Rzeszotarska, B., Smelka, L., and Rospenk, M. (1997) J. Peptide Res. 50, 342-351[Medline] [Order article via Infotrieve] |
| 39. |
Fahey, R. C.,
Brown, W. C.,
Adams, W. B.,
and Worsham, M. B.
(1978)
J. Bacteriol.
133,
1126-1129 |
| 40. |
Genghof, D. S.
(1970)
J. Bacteriol.
103,
475-478 |
| 41. | Newton, G. L., Bewley, C. A., Dwyer, T. J., Horn, R., Aharonowitz, Y., Cohen, G., Davies, J., Faulkner, D. J., and Fahey, R. C. (1995) Eur. J. Biochem. 230, 821-825[Medline] [Order article via Infotrieve] |
| 42. | Spies, H. S. S., and Steenkamp, D. J. (1994) Eur. J. Biochem. 224, 203-213[Medline] [Order article via Infotrieve] |
| 43. | Bardwell, J. C. A. (1994) Mol. Microbiol. 14, 199-205[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Fahey, R. C. S., A. R. (1991) Adv. Enzymol. 64, 1-53 |
| 45. | Perham, R. N. (1991) Biochemistry 30, 8501-8512[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Reed, L. J. (1974) Acc. Chem. Res. 7, 40-46 |
| 47. | Thomas, J. A., Poland, B., and Honzatko, R. (1995) Arch. Biochem. Biophys. 319, 1-9[CrossRef][Medline] [Order article via Infotrieve] |
| 48. |
George, J. W.,
Ghate, S.,
Matson, S.,
and Besterman, J. M.
(1992)
J. Biol. Chem.
267,
10683-10689 |
| 49. |
Guilefoile, P. G.,
and Hutchinson, C.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
8553-8557 |
| 50. |
Petska, S.
(1969)
Proc. Natl. Acad. Sci U. S. A.
64,
709-714 |
| 51. | Monro, R., Celma, M. L., and Vazquez, D. (1969) Nature 222, 356-358[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Herner, A. E., Goldberg, I. H., and Cohen, L. B. (1969) Biochemistry 8, 1335-1344[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Plater, R., and Robinson, J. A. (1992) Gene (Amst.) 112, 117[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Selva, E., Beretta, G., Montanini, N., Saddler, G. S., Gastaldo, L., Ferrari, P., Lorenzetti, R., Landini, P., Ripamonti, F., and Goldstein, B. P. (1991) J. Antibiot. 44, 693-701[Medline] [Order article via Infotrieve] |
| 55. | Kettenring, J., Colombo, U., Ferrari, P., Tavecchia, P., Nebuloni, P., Vekey, K., Gallo, G. G., and Selva, E. (1991) J. Antibiot. 44, 702-715[Medline] [Order article via Infotrieve] |
| 56. | Hofs, H. P. (1997) Anticancer Drugs 8, 349-357[Medline] [Order article via Infotrieve] |
| 57. | Aubel-Sadron, G. (1984) Biochimie 66, 333-352[Medline] [Order article via Infotrieve] |
| 58. | Bannister, E. R. (1966) Can. J. Microbiol. 12, 595-604[Medline] [Order article via Infotrieve] |
| 59. | Kunst, F., et al.. (1997) Nature 390, 249-256[CrossRef][Medline] [Order article via Infotrieve] |
| 60. |
Zalacain, M.,
Gonzalez, A.,
Guerrero, M. C.,
Malpartida, F.,
and Jiménez, A.
(1986)
Nucleic Acids Res.
14,
1565-1581 |
This article has been cited by other articles:
![]() |
A. K. P. Harris, N. R. Williamson, H. Slater, A. Cox, S. Abbasi, I. Foulds, H. T. Simonsen, F. J. Leeper, and G. P. C. Salmond The Serratia gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species- and strain-dependent genome context variation Microbiology, November 1, 2004; 150(11): 3547 - 3560. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ali, P. R. Herron, M. C. Evans, and P. J. Dyson Osmotic regulation of the Streptomyces lividans thiostrepton-inducible promoter, ptipA Microbiology, February 1, 2002; 148(2): 381 - 390. |